Stephane Bancel

Stéphane Bancel joined Moderna Therapeutics in 2011 after learning of their novel platform developing messenger RNA therapeutics™, leaving behind his position as CEO of leading diagnostics company, bioMérieux. Under Mr. Bancel’s leadership, Moderna Therapeutics has brought together a team of industry leaders and raised significant venture funding.

Stéphane Bancel is named as an inventor on over 45 patent filings in the field of messenger RNA technology, the breakthrough arena in which Moderna Therapeutics is developing therapies. Development of mRNA therapeutics creates the ability to produce therapeutic proteins in vivo, allowing for drug development in multiple disease areas including cardiovascular, oncology, and rare diseases.

Previously, Stéphane Bancel was CEO of bioMérieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, led the company through 10 successful acquisitions in the U.S., Europe and Asia/Pacific, and nearly doubled the company’s sales growth rate. Mr. Bancel also enhanced bioMérieux’s position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. Prior to his time at bioMérieux, Stéphane Bancel was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis.

Stéphane Bancel is also executive chairman of the board for portfolio company BG Medicine, focused on the development of biomarker-based diagnostics to improve patient outcomes and contain healthcare costs, as well a Senior Partner of leading venture capital firm Flagship Ventures.

Stéphane Bancel holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Elected a 2009 Young Global Leader by the World Economic Forum in France, Stéphane Bancel has received a number of professional honors, including Best CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.